ArticleJournal of clinical microbiology2026
Comparative performance of CMV IgM and IgG avidity assays for diagnosing a recent primary infection in the first trimester of pregnancy.
Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
First-trimester (T1) cytomegalovirus (CMV) screening relies on IgG, IgM, and IgG avidity testing, but assay performance may vary according to the infection timing. To evaluate the ability of two IgM and three IgG avidity assays to detect maternal primary CMV infection (MPI) occurring in T1 or the periconceptional period. We analyzed 176 serum samples from 94 pregnant women with precisely dated MPI based on seroconversion. Samples were tested using two IgM assays (LIAISON CMV IgM II, Alinity i CMV IgM) and three IgG avidity assays (VIDAS CMV IgG Avidity II, LIAISON CMV IgG Avidity II, Alinity i CMV IgG avidity). For detection of MPI within 4 months, the IgM sensitivity was 99% (122/123) with LIAISON and 92% (94/102) with Alinity i. IgG avidity sensitivity for excluding MPI <4 months was 99% (124/125) with LIAISON, 98% (121/123) with VIDAS, and 92% (111/120) with Alinity i. The positive predictive value of low avidity was highest with VIDAS, followed by LIAISON and Alinity i. Retesting intermediate-avidity results with a second assay improved the estimation of MPI timing. All three avidity assays reliably excluded T1 MPI. Alinity i showed reduced sensitivity for ruling out periconceptional infection, supporting confirmatory testing in equivocal cases. IMPORTANCE: In the context of universal first-trimester cytomegalovirus (CMV) screening and the demonstrated efficacy of valacyclovir to prevent vertical transmission, reliable identification of recent maternal primary infection has become crucial. In this study, we compared the performance of two CMV IgM kits (LIAISON CMV IgM II [DiaSorin]; Alinity i CMV IgM [Abbott Diagnostics]) and three CMV IgG avidity kits (LIAISON CMV IgG Avidity II [DiaSorin]; VIDAS CMV IgG Avidity II [Biomérieux]; Alinity i CMV IgG avidity [Abbott Diagnostics]). Our study assesses the performance of commonly used CMV IgM and IgG avidity assays in a large cohort of pregnant women with precisely dated primary infections, a setting rarely available for assay validation. We provide gestational age-specific performance data and highlight the limited positive predictive value of intermediate-IgG avidity results. Based on these findings, we propose a pragmatic diagnostic algorithm aimed at reducing misclassification and inappropriate clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.